MY147970A - 2'-fluoro-2'deoxytetrahydrouridines as cytidine deaminase inhibitors - Google Patents

2'-fluoro-2'deoxytetrahydrouridines as cytidine deaminase inhibitors

Info

Publication number
MY147970A
MY147970A MYPI2010001528A MYPI20101528A MY147970A MY 147970 A MY147970 A MY 147970A MY PI2010001528 A MYPI2010001528 A MY PI2010001528A MY PI20101528 A MYPI20101528 A MY PI20101528A MY 147970 A MY147970 A MY 147970A
Authority
MY
Malaysia
Prior art keywords
deoxytetrahydrouridines
fluoro
cytidine deaminase
deaminase inhibitors
compounds
Prior art date
Application number
MYPI2010001528A
Other languages
English (en)
Inventor
Gregory S Hamilton
Tsukamoto Takashi
Dana V Ferraris
Duvall Bridget
Lapidus Rena
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY147970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of MY147970A publication Critical patent/MY147970A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2010001528A 2007-10-16 2008-10-16 2'-fluoro-2'deoxytetrahydrouridines as cytidine deaminase inhibitors MY147970A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16

Publications (1)

Publication Number Publication Date
MY147970A true MY147970A (en) 2013-02-28

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010001528A MY147970A (en) 2007-10-16 2008-10-16 2'-fluoro-2'deoxytetrahydrouridines as cytidine deaminase inhibitors

Country Status (39)

Country Link
US (4) US8268800B2 (cg-RX-API-DMAC7.html)
EP (2) EP2447272B1 (cg-RX-API-DMAC7.html)
JP (2) JP5496899B2 (cg-RX-API-DMAC7.html)
KR (1) KR101543049B1 (cg-RX-API-DMAC7.html)
CN (1) CN101827856B (cg-RX-API-DMAC7.html)
AT (1) ATE548374T1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818672B8 (cg-RX-API-DMAC7.html)
CA (1) CA2702274C (cg-RX-API-DMAC7.html)
CO (1) CO6270330A2 (cg-RX-API-DMAC7.html)
CR (1) CR11427A (cg-RX-API-DMAC7.html)
CY (3) CY1112781T1 (cg-RX-API-DMAC7.html)
DK (1) DK2207786T3 (cg-RX-API-DMAC7.html)
EA (1) EA018757B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010095A (cg-RX-API-DMAC7.html)
ES (2) ES2384011T3 (cg-RX-API-DMAC7.html)
FI (2) FIC20230040I1 (cg-RX-API-DMAC7.html)
FR (2) FR23C1052I2 (cg-RX-API-DMAC7.html)
GT (1) GT201000088A (cg-RX-API-DMAC7.html)
HR (1) HRP20120419T1 (cg-RX-API-DMAC7.html)
HU (2) HUS2300045I1 (cg-RX-API-DMAC7.html)
IL (1) IL204732A (cg-RX-API-DMAC7.html)
JO (1) JO2778B1 (cg-RX-API-DMAC7.html)
LT (2) LTC2207786I2 (cg-RX-API-DMAC7.html)
ME (1) ME00997B (cg-RX-API-DMAC7.html)
MX (1) MX2010004109A (cg-RX-API-DMAC7.html)
MY (1) MY147970A (cg-RX-API-DMAC7.html)
NI (1) NI201000055A (cg-RX-API-DMAC7.html)
NL (2) NL301257I2 (cg-RX-API-DMAC7.html)
NO (2) NO2023048I1 (cg-RX-API-DMAC7.html)
NZ (1) NZ584229A (cg-RX-API-DMAC7.html)
PL (1) PL2207786T3 (cg-RX-API-DMAC7.html)
PT (1) PT2207786E (cg-RX-API-DMAC7.html)
RS (1) RS52323B (cg-RX-API-DMAC7.html)
SA (1) SA08290661B1 (cg-RX-API-DMAC7.html)
SI (1) SI2207786T1 (cg-RX-API-DMAC7.html)
TW (1) TWI445539B (cg-RX-API-DMAC7.html)
UA (1) UA99476C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009052287A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002178B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
LT3692983T (lt) 2008-05-15 2021-11-10 Celgene Corporation Citidino analogų peroralinės kompozicijos ir jų naudojimo būdai
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
BRPI0923815A2 (pt) * 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
JP5730854B2 (ja) * 2009-04-06 2015-06-10 大塚製薬株式会社 デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
US8329665B2 (en) * 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
ES2593088T3 (es) * 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
LT2609923T (lt) 2010-03-31 2017-09-11 Gilead Pharmasset Llc (s)-izopropilo 2-(((s)-(perfluorfenoksi)(fenoksi)fosforil)amino)-propanoato kristalinimo būdas
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
CA2840242C (en) 2011-09-16 2019-03-26 Gilead Sciences, Inc. Methods for treating hcv
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP3650013A1 (en) 2013-01-31 2020-05-13 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
CN105683209B (zh) 2013-10-29 2019-03-08 大塚制药株式会社 2’-脱氧-2’,2’-二氟四氢尿苷的合成途径
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
FI3182996T3 (fi) 2014-08-22 2023-03-28 Celgene Corp Menetelmiä multippelin myelooman hoitamiseksi immuunivastetta muuntavilla yhdisteillä yhdistelmässä vasta-aineiden kanssa
DK3383406T3 (da) 2015-12-03 2022-01-10 Epidestiny Inc Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
EA202091856A1 (ru) 2018-02-02 2020-12-07 Маверикс Онколоджи, Инк. Низкомолекулярные лекарственные коньюгаты гемцитабина монофосфата
JP2021535395A (ja) * 2018-08-28 2021-12-16 エッセンリックス コーポレーション アッセイ精度向上
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
KR102280330B1 (ko) * 2018-10-19 2021-07-21 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
WO2020080912A1 (ko) * 2018-10-19 2020-04-23 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
CN114728997B (zh) 2019-10-08 2025-05-23 大塚制药株式会社 高纯度2’-脱氧-2’,2’-二氟四氢尿苷及其制造方法
US12239653B2 (en) * 2020-02-25 2025-03-04 Taiho Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms
IL307181A (en) * 2021-03-26 2023-11-01 Cleveland Clinic Found Treatment of RNA virus infection with a cytidine deaminase inhibitor
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
WO2023069529A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
KR20250053870A (ko) 2022-08-31 2025-04-22 다이호야쿠힌고교 가부시키가이샤 톨리나판트, 세다주리딘 및 데시타빈을 사용한 t 세포 림프종의 치료를 위한 조합 요법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) * 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1985001871A1 (en) 1983-10-26 1985-05-09 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
ATE92499T1 (de) 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
CA2086233C (en) 1991-04-23 1995-10-17 Wendy Oglevee-O'donovan In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
CA2118490A1 (en) 1993-02-23 1994-09-01 Lawrence C. Sowers 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
AU3354500A (en) 1999-03-01 2000-09-21 Halogenetics, Inc. Dramatic simplification of a method to treat neoplastic disease by radiation
AU7018800A (en) 1999-08-26 2001-03-19 Omega Critical Care Limited Improvements relating to catheter positioning
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN100368422C (zh) 2000-11-29 2008-02-13 三井化学株式会社 L-核酸衍生物及其合成方法
ES2236481T3 (es) 2001-01-16 2005-07-16 Glaxo Group Limited Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer.
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
WO2003012051A2 (en) * 2001-07-31 2003-02-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Inhibitor of dna methylation
WO2003068162A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
EP1545558A4 (en) 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
WO2005115410A2 (en) * 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
TW200606159A (en) 2004-07-30 2006-02-16 Pharmaessentia Corp Stereoselective synthesis of β-nucleosides
EP1819718A1 (en) 2004-12-08 2007-08-22 Sicor Inc. Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
JP5730854B2 (ja) 2009-04-06 2015-06-10 大塚製薬株式会社 デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用
US8329665B2 (en) 2009-04-06 2012-12-11 Eisai Inc. Compositions and methods for treating cancer
ES2593088T3 (es) 2009-04-06 2016-12-05 Otsuka Pharmaceutical Co., Ltd. Derivados de (2'-Desoxi-Ribofuranosil)-1,3,4,7-Tetrahidro-(1,3)Diazepin-2-ona para Tratamiento de Cáncer

Also Published As

Publication number Publication date
IL204732A (en) 2013-07-31
JP5496899B2 (ja) 2014-05-21
ES2384011T3 (es) 2012-06-28
EP2447272A1 (en) 2012-05-02
ME00997B (me) 2012-10-20
FR23C1051I1 (fr) 2024-01-26
BRPI0818672A2 (pt) 2015-04-14
US8268800B2 (en) 2012-09-18
US8951987B2 (en) 2015-02-10
AU2008312435A8 (en) 2014-07-24
FIC20230040I1 (fi) 2023-12-22
JP2011500713A (ja) 2011-01-06
LTPA2023538I1 (cg-RX-API-DMAC7.html) 2024-02-26
CO6270330A2 (es) 2011-04-20
JP2014177455A (ja) 2014-09-25
FIC20230039I1 (fi) 2023-12-22
SA08290661B1 (ar) 2012-06-10
NL301257I2 (nl) 2025-11-06
EP2447272B1 (en) 2017-02-01
MX2010004109A (es) 2010-08-10
NL301256I1 (cg-RX-API-DMAC7.html) 2024-01-03
US8618075B2 (en) 2013-12-31
KR20100091978A (ko) 2010-08-19
IL204732A0 (en) 2010-11-30
HK1146410A1 (en) 2011-06-03
ZA201002178B (en) 2011-05-25
SI2207786T1 (sl) 2012-10-30
BRPI0818672B8 (pt) 2021-05-25
CR11427A (es) 2010-08-16
ATE548374T1 (de) 2012-03-15
RS52323B (sr) 2012-12-31
JO2778B1 (en) 2014-03-15
FR23C1052I2 (fr) 2025-02-07
CN101827856B (zh) 2013-02-06
CA2702274C (en) 2015-12-29
WO2009052287A1 (en) 2009-04-23
US20140186335A1 (en) 2014-07-03
US20120289475A1 (en) 2012-11-15
UA99476C2 (en) 2012-08-27
AU2008312435B2 (en) 2014-04-17
NO2023048I1 (en) 2023-12-21
PL2207786T3 (pl) 2012-09-28
TWI445539B (zh) 2014-07-21
ES2616566T3 (es) 2017-06-13
CY2023028I1 (el) 2024-02-16
EA201000642A1 (ru) 2010-10-29
NI201000055A (es) 2010-08-13
EP2207786A1 (en) 2010-07-21
LTPA2023539I1 (cg-RX-API-DMAC7.html) 2024-02-26
US20090137521A1 (en) 2009-05-28
EA018757B1 (ru) 2013-10-30
US9567363B2 (en) 2017-02-14
CY1112781T1 (el) 2016-02-10
NL301256I2 (nl) 2024-01-11
EP2207786B1 (en) 2012-03-07
FR23C1051I2 (fr) 2025-02-07
PT2207786E (pt) 2012-05-28
AU2008312435A1 (en) 2009-04-23
FR23C1052I1 (fr) 2024-01-26
HRP20120419T1 (hr) 2012-07-31
HUS2300044I1 (hu) 2024-01-28
LTC2207786I2 (cg-RX-API-DMAC7.html) 2025-09-10
GT201000088A (es) 2012-03-13
NO2023047I1 (no) 2023-12-21
CA2702274A1 (en) 2009-04-23
TW200924786A (en) 2009-06-16
DK2207786T3 (da) 2012-06-18
HUS2300045I1 (hu) 2024-01-28
CY2023029I1 (el) 2024-02-16
KR101543049B1 (ko) 2015-08-07
NZ584229A (en) 2012-06-29
ECSP10010095A (es) 2010-07-30
US20150210730A1 (en) 2015-07-30
CN101827856A (zh) 2010-09-08
BRPI0818672B1 (pt) 2020-10-20
JP5859588B2 (ja) 2016-02-10

Similar Documents

Publication Publication Date Title
MY147970A (en) 2'-fluoro-2'deoxytetrahydrouridines as cytidine deaminase inhibitors
UA97502C2 (ru) Кристаллическая твердая основа разагилина
WO2008049116A3 (en) Substituted indoles
MY148634A (en) Pyridazinone derivatives
NO20090596L (no) Antivirale fosfinatforbindelser
JO3181B1 (ar) مشتقات كمحول ثاني الكيل البايردينيل - أحادي الفينيل كأنزيم ثنائي استرات الفوسفود
WO2007125103A3 (en) Benzamide glucokinase activators
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
MX2009010174A (es) Derivados de aza-adamantano ester y carbamato y metodos de uso de los mismos.
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
TW200634023A (en) Amide prodrug of gemcitabine, compositions and use thereof
MY142105A (en) Leukotriene biosynthesis inhibitors
TW200740814A (en) Compounds
MX2009000198A (es) Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo.
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
EP2069346A4 (en) ACETAMIDE AND CARBOXAMIDE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
NO20091386L (no) Fenyloksyanilinderivater
WO2008083191A3 (en) Radiofluorination methods
ZA200903193B (en) Novel Morphine derivatives
AU2015201137B2 (en) Compositions and method for tissue preservation
UA97521C2 (ru) и-РНК-АГЕНТ, КОТОРЫЙ ОПОСРЕДУЕТ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC